Curated News
By: NewsRamp Editorial Staff
April 17, 2024
Theriva™ Biologics Hits Several Milestones in 2023, Positioning Itself for Growth as the Firm Targets Difficult-to-Treat Cancers
TLDR
- Theriva™ Biologics achieved several milestones in 2023, potentially positioning it for a strong year ahead, providing a competitive advantage in the field of immuno-oncology.
- Theriva's oncolytic viruses can overcome the protective barrier surrounding solid tumors and selectively kill tumor cells, potentially revolutionizing cancer treatment.
- Theriva's developmental therapies have the potential to enhance current standard-of-care therapies and deliver promising treatments for very difficult-to-treat cancers, making tomorrow better than today.
- More than 100 patients have been dosed with VCN-01 in clinical trials, showing promising progress in the treatment of a broad range of cancers.
Impact - Why it Matters
The achievements of Theriva™ Biologics in 2023, particularly with the advancement of VCN-01 and the expansion of collaborations, signal promising progress in the development of therapies for difficult-to-treat cancers. The positive safety recommendations and enrollment progress in clinical trials of VCN-01 offer hope for improved treatment options for patients with pancreatic, retinoblastoma, head and neck, brain, and ovarian cancers. The company's efforts to address unmet needs for difficult-to-treat cancers have the potential to significantly impact the future of cancer treatment.
Summary
Theriva™ Biologics (AMEX: TOVX), the clinical-stage immuno-oncology company, has achieved several milestones in 2023, positioning itself for a strong year ahead. The company's lead therapy candidate, VCN-01, is currently in a phase 2b trial for the treatment of patients with pancreatic ductal adenocarcinoma (PDAC) and in investigator-sponsored studies in a number of indications. The trial is on track to complete enrollment in the first half of this year, with positive safety recommendations from the Independent Data Monitoring Committee.
Theriva is also engaged in a phase 1 trial evaluating the safety and activity of intravitreal VCN-01 in pediatric patients with refractory retinoblastoma, and dosing is underway for the ongoing phase 1b/2a randomized clinical trial of SYN-004 (ribaxamase) in allogeneic hematopoietic cell transplant recipients. Additionally, the company has expanded collaborations and identified new areas that may benefit from VCN-01, including an exclusive option to license intellectual property from Sant Joan de Déu-Barcelona Children’s Hospital.
Source Statement
This curated news summary relied on this press release disributed by News Direct. Read the source press release here, Theriva™ Biologics Hits Several Milestones in 2023, Positioning Itself for Growth as the Firm Targets Difficult-to-Treat Cancers
